Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)

E Richtig; R Gutzmer; C Loquai; JS Utikal; C Holler; R Stadler; A Forschner; JC Hassel; Dirk Debus; D Goppner; M Fluck; S Haferkamp; M Kaatz; M Welslau; R Dummer; R von Moos; A Schmidt; L Milde; O Michielin; D Schadendorf

Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)

E Richtig, R Gutzmer, C Loquai, JS Utikal, C Holler, R Stadler, A Forschner, JC Hassel, Dirk Debus, D Goppner, M Fluck, S Haferkamp, M Kaatz, M Welslau, R Dummer, R von Moos, A Schmidt, L Milde, O Michielin, D Schadendorf

Universitätsklinik für Dermatologie

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

Originalsprache	Deutsch
Seiten (von - bis)	53-53
Fachzeitschrift	JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
Jahrgang	19
Publikationsstatus	Veröffentlicht - 2021

Dieses zitieren

Richtig, E., Gutzmer, R., Loquai, C., Utikal, JS., Holler, C., Stadler, R., Forschner, A., Hassel, JC., Debus, D., Goppner, D., Fluck, M., Haferkamp, S., Kaatz, M., Welslau, M., Dummer, R., von Moos, R., Schmidt, A., Milde, L., Michielin, O., & Schadendorf, D. (2021). Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 19, 53-53.

Richtig, E ; Gutzmer, R ; Loquai, C et al. / Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA). in: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2021 ; Jahrgang 19. S. 53-53.

@article{ed8489f258054cc7bf7f5ea5f0098e88,

title = "Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)",

author = "E Richtig and R Gutzmer and C Loquai and JS Utikal and C Holler and R Stadler and A Forschner and JC Hassel and Dirk Debus and D Goppner and M Fluck and S Haferkamp and M Kaatz and M Welslau and R Dummer and {von Moos}, R and A Schmidt and L Milde and O Michielin and D Schadendorf",

year = "2021",

language = "Deutsch",

volume = "19",

pages = "53--53",

journal = "JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT",

issn = "1610-0379",

publisher = "Wiley Verlag ",

}

Richtig, E, Gutzmer, R, Loquai, C, Utikal, JS, Holler, C, Stadler, R, Forschner, A, Hassel, JC, Debus, D, Goppner, D, Fluck, M, Haferkamp, S, Kaatz, M, Welslau, M, Dummer, R, von Moos, R, Schmidt, A, Milde, L, Michielin, O & Schadendorf, D 2021, 'Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)', JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Jg. 19, S. 53-53.

Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA). / Richtig, E; Gutzmer, R; Loquai, C et al.
in: JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, Jahrgang 19, 2021, S. 53-53.

Publikation: Beitrag in Fachzeitschrift › publizierter Abstrakt (Zeitschrift) › Begutachtung

TY - JOUR

T1 - Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA)

AU - Richtig, E

AU - Gutzmer, R

AU - Loquai, C

AU - Utikal, JS

AU - Holler, C

AU - Stadler, R

AU - Forschner, A

AU - Hassel, JC

AU - Debus, Dirk

AU - Goppner, D

AU - Fluck, M

AU - Haferkamp, S

AU - Kaatz, M

AU - Welslau, M

AU - Dummer, R

AU - von Moos, R

AU - Schmidt, A

AU - Milde, L

AU - Michielin, O

AU - Schadendorf, D

PY - 2021

Y1 - 2021

M3 - publizierter Abstrakt (Zeitschrift)

SN - 1610-0379

VL - 19

SP - 53

EP - 53

JO - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

JF - JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

ER -

Richtig E, Gutzmer R, Loquai C, Utikal JS, Holler C, Stadler R et al. Encorafenib plus Binimetinib in Patients with locally advanced, non-resectable or metastatic BRAF(V600) mutated Melanoma: first Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERING(MELANOMA). JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT. 2021;19:53-53.